Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Payables (2016 - 2025)

Historic Payables for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $1.9 million.

  • Enanta Pharmaceuticals' Payables fell 7565.61% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 7565.61%. This contributed to the annual value of $1.9 million for FY2025, which is 7565.61% down from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Payables is $1.9 million, which was down 7565.61% from $3.5 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Payables peaked at $11.8 million during Q1 2023, and registered a low of $1.2 million during Q2 2022.
  • For the 5-year period, Enanta Pharmaceuticals' Payables averaged around $6.3 million, with its median value being $6.0 million (2022).
  • Per our database at Business Quant, Enanta Pharmaceuticals' Payables tumbled by 7888.04% in 2022 and then soared by 53710.84% in 2023.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Payables stood at $7.8 million in 2021, then tumbled by 44.5% to $4.4 million in 2022, then skyrocketed by 114.29% to $9.3 million in 2023, then tumbled by 49.32% to $4.7 million in 2024, then crashed by 58.78% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $3.5 million for Q2 2025, and $4.8 million during Q1 2025.